美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

SL Science Holding Ltd

1.90

-0.0100-0.52%

成交量：8,750

成交額：1.65萬

市值：10.64億

市盈率：-2.95

高：1.92

開：1.91

低：1.86

收：1.91

52周最高：14.50

52周最低：1.85

股本：5.60億

流通股本：2.27億

量比：0.15

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.6447

每股收益(LYR):-0.4532

淨資產收益率：-25.62%

總資產收益率：-14.70%

市淨率：224.92

市盈率(LYR):-4.19

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

SL Science披露GDT細胞外泌體新FDA藥物主文件，平台監管基礎進一步夯實

SL Science於2026年世界基礎與臨床藥理學大會成功展示突破性腦癌療法研究成果

SL Science Holding Limited向美國FDA提交針對膠質母細胞瘤的GDT細胞療法孤兒藥資格認定申請

異動解讀 | 完成SPAC合併後市場情緒逆轉，HORIZON SPACE ACQUISITION II Corp盤中暴漲229.18%

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/SLBT"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SLBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLBT\",,,,,undefined,":{"symbol":"SLBT","market":"US","secType":"STK","nameCN":"SL Science Holding Ltd","latestPrice":1.9,"timestamp":1789574220293,"preClose":1.91,"halted":0,"volume":8750,"delay":0,"changeRate":-0.005235602094240842,"floatShares":226857620,"shares":560000000,"eps":-0.644729,"marketStatus":"交易中","change":-0.01,"latestTime":"09-16 12:00:08 EDT","open":1.91,"high":1.92,"low":1.86,"amount":16506.679,"amplitude":0.031414,"askPrice":1.95,"askSize":200,"bidPrice":1.89,"bidSize":23,"shortable":0,"etf":0,"ttmEps":-0.644729,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":1.91,"preHourTrading":{"tag":"盘前","latestPrice":1.97,"preClose":1.91,"latestTime":"09:02 EDT","volume":136,"amount":260.6700032,"timestamp":1789563721833,"change":0.06,"changeRate":0.031414,"amplitude":0.04712},"postHourTrading":{"tag":"盘后","latestPrice":2.02,"preClose":1.91,"latestTime":"19:30 EDT","volume":1107,"amount":2236.5216,"timestamp":1789515006579,"change":0.11,"changeRate":0.057592,"amplitude":0.057592},"volumeRatio":0.149934},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLBT\",,,,,undefined,":{"symbol":"SLBT","floatShares":226857620,"roa":"-14.70%","roe":"-25.62%","lyrEps":-0.453239,"volumeRatio":0.149934,"shares":560000000,"dividePrice":0,"high":1.92,"amplitude":0.031414,"preClose":1.91,"low":1.86,"week52Low":1.85,"pbRate":"224.92","psRate":"325.37","week52High":14.5,"institutionHeld":0,"latestPrice":1.9,"committee":-0.793722,"eps":-0.644729,"divideRate":0,"volume":8750,"delay":0,"ttmEps":-0.644729,"open":1.91,"prevYearClose":10.545,"prevWeekClose":2.06,"prevMonthClose":2.73,"prevQuarterClose":4.79,"fiveDayClose":2.61,"twentyDayClose":2.72,"sixtyDayClose":4.52},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLBT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLBT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLBT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLBT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLBT","date":"2026-09-15","current":-2.946975,"percent":0.558824,"low":-791.521742,"twenty":-648.521742,"median":-621.739133,"eighty":-363.724186,"high":-182.131353,"avg":-505.756698,"sd":178.38716,"marketCap":1172844094},"quantilePoints":[{"date":"2026-07-31","current":-364.945192,"twenty":-373.627903,"median":-369.015213,"eighty":-360.061167,"marketCap":434771250},{"date":"2026-08-07","current":-370.371886,"twenty":-395.063345,"median":-373.085233,"eighty":-362.50318,"marketCap":441236250},{"date":"2026-08-14","current":-184.859913,"twenty":-376.612585,"median":-361.892676,"eighty":-183.768489,"marketCap":438003750},{"date":"2026-08-21","current":-648.043481,"twenty":-637.043481,"median":-373.085233,"eighty":-189.77132,"marketCap":1535462558},{"date":"2026-08-28","current":-631.30435,"twenty":-637.043481,"median":-398.862031,"eighty":-288.859314,"marketCap":1495801164},{"date":"2026-09-04","current":-753.260872,"twenty":-649.000003,"median":-621.739133,"eighty":-356.398148,"marketCap":1784762752},{"date":"2026-09-11","current":-502.173915,"twenty":-649.478263,"median":-624.130437,"eighty":-361.282173,"marketCap":1189841835},{"date":"2026-09-15","current":-495.000002,"twenty":-648.521742,"median":-621.739133,"eighty":-363.724186,"marketCap":1172844094}],"updateTime":1789574408313},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLBT\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1105965981","title":"SL Science披露GDT細胞外泌體新FDA藥物主文件，平台監管基礎進一步夯實","url":"https://stock-news.laohu8.com/highlight/detail?id=1105965981","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105965981?lang=zh_tw&edition=fundamental","pubTime":"2026-08-27 20:01","pubTimestamp":1787832086,"startTime":"0","endTime":"0","summary":"SL Science近日对外界公布了一项重要进展——该公司已为GDT细胞来源的外泌体提交了全新的美国食品药品监督管理局药物主文件。此举被视为其平台在监管合规层面迈出的又一步，为后续产业化进程提供了更为坚实的制度支撑。值得关注的是，这份新备案的药物主文件并非孤立动作。SL Science此番抢先完成相关备案，无疑为其在合规竞争中占得先机。随着监管框架的逐步完善，外泌体赛道或将迎来新一轮洗牌。SL Science的这一步，或许正是其谋篇布局的关键一环。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141470862","title":"SL Science於2026年世界基礎與臨床藥理學大會成功展示突破性腦癌療法研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=1141470862","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141470862?lang=zh_tw&edition=fundamental","pubTime":"2026-07-17 20:04","pubTimestamp":1784289856,"startTime":"0","endTime":"0","summary":"SL Science宣布，在2026年世界基础与临床药理学大会上，其突破性脑癌疗法的研究已成功完成展示。该成果标志着公司在神经肿瘤治疗领域的创新探索取得了重要阶段性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119449177","title":"SL Science Holding Limited向美國FDA提交針對膠質母細胞瘤的GDT細胞療法孤兒藥資格認定申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1119449177","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119449177?lang=zh_tw&edition=fundamental","pubTime":"2026-07-10 20:02","pubTimestamp":1783684977,"startTime":"0","endTime":"0","summary":"SL Science Holding Limited已正式向美国食品药品监督管理局提交申请，为其针对胶质母细胞瘤的GDT细胞疗法寻求孤儿药资格认定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161290456","title":"異動解讀 | 完成SPAC合併後市場情緒逆轉，HORIZON SPACE ACQUISITION II Corp盤中暴漲229.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161290456","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161290456?lang=zh_tw&edition=fundamental","pubTime":"2026-06-16 23:03","pubTimestamp":1781622193,"startTime":"0","endTime":"0","summary":"HORIZON SPACE ACQUISITION II Corp  今日盘中股价大幅飙升，涨幅高达229.18%，市场表现极为抢眼。这一惊人的上涨行情，紧随该公司通过特殊目的收购公司方式完成与SL Science的业务合并之后。市场情绪在短时间内发生了剧烈切换，从前一交易日的恐慌性抛售迅速转为积极的买入行为，从而推动了股价实现显著的V型反弹。这反映出在SPAC上市过程中，市场正在对公司的估值进行激烈的重估和寻找新的平衡点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SLBT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/SLBT\",params:#limit:6,delay:false,,,undefined,":[]}}